Seventure set for 200 million euro vote of confidence in microbiome R&D

6 March 2019

French life sciences investment group Seventure Partners is already halfway to reaching its goal of raising 200 million euros ($227 million) for its microbiome-focused Health for Life Capital II fund.

The first Health for Life fund raised around 160 million euros, and the continued appetite for investment in this area signals high expectations for the therapeutic potential of research into the human microbiome.

The original fund attracted strategic investments from organizations including Danone, Novartis (NOVN: VX), Lesaffre, and others. The new fund features many of the same partners plus new investors including Limited Partners.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK